




>>Entry Name: Lipstatin

Synonym(s): *N*-Formylleucine 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]-3,6-dodecadienyl ester, 9Cl



CAS Registry Number: 96829-59-3

Molecular Formula: C<sub>29</sub>H<sub>49</sub>NO<sub>5</sub>

Molecular Weight: 491.71

Accurate Mass: 491.361074

Percentage Composition: C 70.84%; H 10.04%; N 2.85%; O 16.27%

Biological Source: Isol. from *Streptomyces toxytricini*

Biological Use/Importance: Inhibits pancreatic lipase activity

Physical Description: Pale-yellow oil

Optical Rotation:  $[\alpha]_D^{20} -19$  (c, 1 in CHCl<sub>3</sub>)

Solubility: BERDY SOL: Sol. MeOH, EtOAc

Calculated Log P Data: Log P 7.07 (uncertain value) (calc)

UV: [neutral]  $\lambda_{\max}$  270 (sh) ( $\epsilon$  34) (EtOH) (Derep) [neutral]  $\lambda_{\max}$  270 () (MeOH) (Berdy)

>>>Derivative: Tetrahydro

Synonym(s): *N*-Formylleucine 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, 9Cl. Tetrahydrolipstatin. Orlipastat, INN. **Orlistat**, BAN, INN, USAN. Xenical. Ro 18-0647

CAS Registry Number: 96829-58-2

Molecular Formula: C<sub>29</sub>H<sub>53</sub>NO<sub>5</sub>

Molecular Weight: 495.741

Accurate Mass: 495.392374

Percentage Composition: C 70.26%; H 10.78%; N 2.83%; O 16.14%

Biological Use/Importance: Pancreatic lipase inhibitor. Used to treat obesity

Development Status: Marketed drug. Launched in New Zealand (1998). Worldwide equal 89th best selling prescription drug (\$0.56 bn) (Hoffmann-La Roche) (2000, Pharma Business)

Melting Point: Mp 43°

Optical Rotation:  $[\alpha]_D^{22} -33$  (c, 1 in CHCl<sub>3</sub>)

Calculated Log P Data: Log P 8.03 (uncertain value) (calc)

References:

- Barbier, P. *et al.*, *Helv. Chim. Acta*, 1987, **70**, 196, (*synth, abs config*)  
Hogan, S. *et al.*, *Int. J. Obes.*, 1987, **11**, 35, (*pharmacol, deriv*)  
Kupfer, E. *et al.*, *J. Antibiot.*, 1987, **40**, 1081; 1086, (*isol, struct, props*)  
Hadváry, P. *et al.*, *Biochem. J.*, 1988, **256**, 357, (*pharmacol*)  
Barbier, P. *et al.*, *J.O.C.*, 1988, **53**, 1218, (*synth, deriv, bibl*)  
Fleming, I. *et al.*, *Tet. Lett.*, 1990, **31**, 3645, (*synth*)  
Chadha, N.K. *et al.*, *J.O.C.*, 1991, **56**, 4714, (*synth*)  
Hauptman, J.B. *et al.*, *Am. J. Clin. Nutr.*, 1992, **55**, Suppl; 309S, (*Orlipastat, pharmacol, human*)  
Lüthi-Peng, Q. *et al.*, *Eur. J. Biochem.*, 1992, **205**, 383, (*Orlipastat, pharmacol*)  
Stalder, H. *et al.*, *Helv. Chim. Acta*, 1992, **75**, 1593, (*Tetrahydrolipstatin, metab*)  
Pommier, A. *et al.*, *Synthesis*, 1994, 1294, (*Tetrahydrolipstatin, synth*)  
Pommier, A. *et al.*, *J.O.C.*, 1995, **60**, 7334, (*synth, bibl, pmr, cmr*)  
McNeely, W. *et al.*, *Drugs*, 1998, **56**, 241-249, (*rev*)  
Ghosh, A.K. *et al.*, *Chem. Comm.*, 1999, 1743-1744, (*synth, Tetrahydrolipstatin*)  
Harp, J.B., *Drugs of Today (Barcelona)*, 1999, **35**, 139-145  
*Martindale, The Extra Pharmacopoeia*, 32nd edn., *Pharmaceutical Press*, 1999, 1611  
Goese, M. *et al.*, *J.O.C.*, 2001, **66**, 4673-4678, (*biosynth*)